Cardiovascular Health
Cardiovascular disease remains a significant area of therapeutic development, requiring models that reflect the complexity of naturally occurring disease while providing clinically relevant endpoints. Transpharmation offers canine cardiovascular research capabilities centered on naturally occurring cardiac disease, supporting the evaluation of therapeutics, biomarkers, and physiological outcomes in a translational setting.
Detail of offering
Transpharmation’s canine colony includes a subpopulation with naturally occurring ACVIM Stage B1-B2 Mitral Valve Disease, a condition that shares important features with human cardiovascular disease. This spontaneous model enables the evaluation of novel cardiovascular therapies in animals with established disease rather than experimentally induced pathology.
Studies can incorporate a range of clinical and physiological assessments, including:
- Veterinary examinations
- Blood pressure measurements
- Collection of biological samples
- Heart rate monitoring
These endpoints provide insight into cardiovascular function, disease progression, and therapeutic response.
Biomarker assessments can be incorporated to characterize cardiac health and treatment effects, including:
- NT-proBNP
- Circulating cardiac troponin-I
- Erythropoietin (EPO)
- Additional blood-based biomarker analysis as required
These measures can support the evaluation of cardiac injury, function, and disease progression.
A range of imaging and monitoring technologies are available to support cardiovascular studies, including:
- Echocardiography performed by a veterinary cardiologist
- Radiography
- Electrocardiography (ECG)
These tools enable detailed assessment of cardiac structure and function throughout a study.
For programs requiring more specialized assessments, Transpharmation also offers:
- Telemetered ECG models for pharmacology studies
- Wireless implant technology for physiological monitoring
- Systemic and left ventricular pressure measurements
- Body temperature and activity monitoring
- Electrophysiology protocols for arrhythmia assessment
These capabilities provide additional opportunities to investigate cardiovascular pharmacology and safety endpoints.
Platforms used
Electroencephalography (EEG) In-vivo rodent telemetry
Imaging Services Companion animal imaging
Operant Platform Motivation, impulsivity, attention, cognition, memory
PK/PD Studies Endpoints for lead optimization
PK-Bridge PK studies for discovery budgets
Cognitive Assessment Aged-dog memory and cognitive decline
Have a program in mind?
Cardiovascular programs often require a combination of clinical assessments, biomarkers, and imaging endpoints to fully understand treatment effects. Contact our team for support identifying the most appropriate study design and cardiovascular measures to support your research objectives and development strategy.